Resources Global Insights

Under Global Insights” we gather strategic analyses, discussions, and materials that reflect the development of the international pharmaceutical industry. Here you’ll find reports, webinars, and e-books offering perspectives from different continents – for those who want to understand the trends shaping the future of health and markets.

WEBINARS

Opportunities in the Chinese pharmaceutical market

Featuring GHN members Bruno Leraillez and Kishor Kumar Shrestha

Opportunities in the Chinese pharmaceutical market must be part of any company’s strategy — whether as a client, a supplier, a competitor, or a partner. Opportunities exist for innovative treatments, orphan drugs, and technology partnerships.

Program

China Pharmaceutcal Market, Dr Bruno LERAILLEZ

Summary/Discussion/Questions

Bruno Leraillez, CEO & founder of Innoledge International Ltd
Based in Hong Kong since 1994. Graduate of ENVA and Paris University of Medicine.

Kishor Kumar Shrestha. Manager Innoledge International
Pharmacist graduated from China Pharmaceutical University (Nanjing).

TO WEBINAR

DIGITAL DISCUSSIONS

How AI is Revolutionizing Global Pharma

CEO Roland Sandström Reveals 50-Year Transformation

Roland Sandström, CEO of GHN Pharma with 50 years in pharmaceuticals, reveals how AI is dismantling Big Pharma’s monopoly and enabling small companies to compete globally. From his early days when everything was manual to today’s AI-powered drug development, he shares unprecedented insights into the pharmaceutical industry’s rapid transformation. Roland Sandström has built and sold three pharmaceutical companies over five decades, witnessing the industry evolve from paper-based processes to AI-driven innovation. As CEO of GHN Pharma, he leads a global network spanning 90 countries, helping pharmaceutical companies navigate complex international markets while leveraging cutting-edge technology. In this eye-opening interview,
he explains:

◽ ️ How AI is reducing drug development timelines from years to months
◽ ️ Why Big Pharma companies are becoming “big banks” rather than innovators
◽ ️ How small pharmaceutical companies can now compete with industry giants
◽ ️ The hidden world of parallel importers disrupting European medicine supply
◽ ️ Why rare disease treatments are becoming the new pharmaceutical goldmine
◽ ️ How personalized medicine will revolutionize patient care within years
◽ ️ The future of pharmaceutical sales without traditional sales force

A Journey Across Five Decades in Pharma

Featured on Growthcast

I had the pleasure to speak with Roland Sandström & Tina Madsen Sandstrøm from GHN Pharma. Their journey of scaling a business within the challenging Pharma landscape, overcoming hurdles, and achieving not one but two successful exits was incredibly inspiring. Thank you for sharing your valuable experiences! 

Alex Lee, Growthcast B2B

 

E-BOOKS

NEW! Voices Across Continents

Future Trends in Pharma & Biotech – GHN 2025. A Global Perspective from GHN Member Interviews. Celebrating 5 Years of Insight and Collaboration. To e-book

GHN helping you Globalise – Part 1 Latin America

Under the theme of GHN Helping you Globalise, GHN will highlight a particular region on a monthly basis. The first region will be Latin America a region that is not so well known, but of high potential. This would be followed by other regions. Our local teams in Latin America are ready to support your expansion efforts. We know the complexities and the need for assistance, not in one but in many different areas such as Legal, Regulatory, Medical, Market Access, Distribution, Supply and local follow up. To e-book

GHN Helping you Globalise – Part 2 Australia and New Zealand

Under the theme of GHN Helping you Globalise, GHN is highlighting particular regions. Welcome to our second edition of Healthy Planet to Healthcare introducing Australia and New Zealand.

CONSIDERING AUSTRALIA & NEW ZEALAND IN YOUR FUTURE STRATEGY? The “Healthy Planet Guide Part 2, Australia & New Zealand”  is the perfect introduction. Read it right here or download it free as a pdf file.

Invest in the GHN Service program including 9 Competence areas.  Define what service you need and PICK YOUR OWN TEAM!  Use the GHN offer of 30 minutes free consultation with our Australian member. To e-Book

GHN helping you Globalise – Part 3, Singapore & Malaysia

Under the theme of GHN Helping you Globalise, GHN is highlighting particular regions. Welcome to our third edition of Healthy Planet to Healthcare introducing Singapore and Malaysia.

CONSIDERING Singapore & Malaysia IN YOUR FUTURE STRATEGY? Start off by reading the GHN e-Book, “Healthy Planet Part 3, Singapore & Malaysia” or download it free as a pdf file.

Invest in the GHN Service program including 9 Competence areas. Define what service you need and PICK YOUR OWN TEAM! Use the GHN offer of 30 minutes free consultation with our Australian member. To e-book

GHN helping you Globalise – Part 4 The Nordics

If you see The Nordic region in your future strategy, read the the GHN eBook, “Healthy Planet, Part 4, The Nordics”  right here or download the book free as a pdf file.

Investing in the Nordic area or introducing new pharmaceutical products in the region can be highly beneficial for pharmaceutical companies due to the following reasons:

1. High-income population: The Nordic countries have a high GDP per capita, and the population has a high purchasing power, making it an attractive market for pharmaceutical products.

2. Advanced healthcare systems: The Nordic countries have well-developed healthcare systems that prioritize patient safety and innovation. This provides a favorable environment for introducing new pharmaceutical products.

3. Favorable regulatory environment: The Nordic countries have a transparent and efficient regulatory framework that prioritizes patient safety while being open to innovation and new technologies.

4. Highly educated and skilled workforce: The Nordic countries have a highly educated and skilled workforce, with a focus on science, technology, engineering, and mathematics (STEM) education.

5. Focus on sustainability and innovation: The Nordic countries prioritize sustainability and innovation, creating a favorable environment for pharmaceutical companies that are committed to developing environmentally sustainable and socially responsible products.

.Overall, establishing a presence in the Nordic area or introducing new pharmaceutical products in the region can provide access to a high-income population, advanced healthcare systems, a favourable regulatory environment, a highly educated and skilled workforce, and a focus on sustainability and innovation, making it a highly rational argument for pharmaceutical companies to consider. To e-book

No results found.
No results found.
TO TALKS KNOWLEDGE NAVIGATOR
×
Ingvar Bosaeus

Martin Björendahl

Marketing

Key Competence

21 years of experience in pharmaceuticals and medical technology, focused on sales and marketing, with an emphasis on product launches and contract negotiations.

Education

Degree in Marketing Economics from IHM, with certifications in pharmacology and leadership.

Experiences

Over 20 years of experience in sales and key accounts, focusing on product launches and specialist networks in neurology and women’s health.

×
Ingvar Bosaeus

Eirik Møglebust Larssen

Marketing

Key Competence

Specialist in the sale of pharmaceuticals and special products from the pharmaceutical industry. Extensive experience with drug launches. Sales and product presentations to medical departments/staff.

Education

Pharmaceutical Consultant in Medicine from University of Oslo.

Experiences
  • 25 years of experience in pharmaceuticals and medical technology, focused on sales and marketing, with an emphasis on product launches
×
Mats Erasmie

Mats Erasmie

Chairman of the board Simplex Motion AB. Consultant in Leadership and Business Development.

Key Competence

Sales, Leadership as a part of a strategic changes.

Education
  • MBA, International marketing, University of Stockholm
  • Certified in Authentic Leadership,Transaction Analysis, Situational Leadership (SL II, Blanchard).
  • Certified in Insight Discovery, Certified in DISC.
Experiences
  • Consultant in Leadership and Business Development.
  • Erasmie&Erasmie AB.
  • Chairman of the board Simplex Motion AB.
  • Consultant at Booster Group AB, business development and negotiations.'
  • Teacher at IHM, Market Analysis, Practical Marketing and Negotiations.
  • CEO, Chairman of the board and partner; Sällma AB.
  • Vice President Marketing & Sales, Consultant in Leadership and Business.
  • Development at Cordovan Performance Sweden AB.
  • CEO at Lucky Punk AB.
Publications

Books and training packages, marketing and sales, twelve in total since 1999

  • ”MED KUNDEN I FOKUS”, Liber Ekonomi 2000.
  • ”KUNDRELATIONEN”, Liber Ekonomi 2001.
  • ”FÖRSÄLJNING OCH SERVICE”, Liber Ekonomi 2003.
  • ”PERSONLIG FÖRSÄLJNING 1”, Liber Ekonomi 2012.
  • ”PERSONLIG FÖRSÄLJNING 2”, Liber Ekonomi 2014.
  • ”Dödskaravanen”, Historical novel, 2018.
  • ”Silverfloden”, Historical novel, 2019.
  • Various articles in the magazines Ledarskap, Affärsvärlden and Dagens Industri.

What Now?

You have defined your interest area and the questions related to this.

Now fill in the form and send it to us. The defined contact person from GHN Pharma Nordic will review your interest and contact you within 48 hours.

×

Get a Contact Person

×
Pontus Bergman

Valdet Hetemi

Head of Operation & Logistics

Key Competence

Over 17 years of experience within the Pharmaceutical industry; Rx, Medical Devices, Metabolic Diseases, OTC, Logistics and Supply Chain, Business Strategy, Finance, Sales and Marketing, Start-Ups.

Education
  • Education: Master of Business Administration and Bachelor of Social Sciences from the University of Lund and University of Cologne.
Experiences
  • Head of Operations at POA Pharma Scandinavia AB, Country Manager Sweden at Vitaflo Scandinavia AB/ Navamedic AB, Finance Manager at Vitaflo Scandinavia AB/Navamedic AB.
×
Ingvar Bosaeus

Martin Svahn

RP& Pharmacist

Key Competence

Martin Svahn is a licensed pharmacist and pharmacy manager.

Education
  • Licensed Pharmacist at University of Uppsala.
  • Magister thesis at the Departement of Anaesthesiology, University of Uppsala.
  • Master's Program in Clinical Pharmacy University of Uppsala.
Experiences
  • Start-up of a new privately owned pharmacy.
  • Worked in 2013 at K3 as GSST
  • Since 2014 pharmacy manager at three pharmacies with responsibility for 13-20 employees and an annual turnover of 80 million.
  • "Cluster manager" for Kronan's pharmacy Halland.
×
Mats Erasmie

Andreas Larsson

Finance Manager

Key Competence

Experience within the Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases and OTC regarding Accounting and Finance Strategy, Financial reporting, Business Development and Logistical support

Education
  • Master of Aeronautical Science at the University of Embry-Riddle Aeronautical University and a degree at the KY academy of finance and accounting at Studium in Gothenburg.
Experiences
  • Accounting manager at POA Pharma Scandinavia AB, POA Pharma North America and Adrian & Partners AB.
×
Pontus Bergman

Pontus Bergman

PB Lawyer, founder of Bergman & Eek Advokat AB.

Key Competence

Principal fields of practice are strategically planning for privately owned companies regarding all legal and economic matters. Special focus on developing and establishing new companies or activities abroad, including international tax law for companies and employees.

 
Education
  • Education: Master of Laws from University of Lund
Experiences
  •  Partner at Setterwalls Law Firm.
  • Director of the board of POA Pharma AB and in several Swedish privately own companies.
×
Tina Madsen Sandström

Tina Madsen Sandström

Founder & CEO

Key Competence
Over 35 years experience within the international Pharmaceutical industry Rx, Medical Devices, OTC and Rare Metabolic Diseases, Administration, Leadership, Licenses & Acquisitions, Start-ups Development, Development, Management.
Education
Merkonom, Educated at Hillerød Business School. M
Experiences
  • Managing Director for Pharma-Vinci A/S, Member of the branch organisation BFID.
  • CEO Vitaflo Scandinavia AB.
  • CEO POA Pharma Scandinavia AB.
  • Director of the board Vitaflo Scandinavia AB.
  • Director of the board POA Consulting AB.
  • Director of the board POA Pharma Scandinavia AB.
×
Roland Sandström

Roland Sandström

Founder & Executive Chairman

Key Competence
45 years experience within the international Pharmaceutical industry; Rx, Medical Devices, Metabolic Diseases, OTC. Commercial Strategy, Business Development, License & Acquisitions, Start-ups Development, Management, Organisation Theory.
Education
Master of Political Science at the University of Lund.
Experiences
  • Managing Director Meda Sweden.
  • Board member of LSAB and LIF.
  • COB and Founder Vitaflo Scandinavia AB.
  • Director of the board Navamedic.
  • COB and Founder POA Pharma Scandinavia AB.
  • COB and Founder POA Pharma North America.
  • COB and Founder GHN Pharma International.
Publications
  • Kunden som Kompis (Customer as a Pal).
  • Articles around Project work, organisation theory and marketing.
  • Lectures and abstract publications at IPMA in Paris and Ljubljana.